SCHEMBL4444437

SCHEMBL4444437

CNC(=O)c1cc2c(cc1F)N(C1CCN(CC(=O)N3C[C@H]4CCC[C@H]4C3)CC1)C(=O)C2

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLD1 Q13393 1/20 0.38
OPRM1 P35372 7/20 0.34
OPRL1 P41146 7/20 0.34
OPRK1 P41145 6/20 0.34
HTR2A P28223 1/20 0.34
HTR7 P34969 1/20 0.34
KCNH2 Q12809 3/20 0.33
SCN9A Q15858 3/20 0.32
SCN10A Q9Y5Y9 1/20 0.32
CHRM4 P08173 2/20 0.32
SCN1A P35498 1/20 0.32
SCN5A Q14524 1/20 0.32
ESR1 P03372 1/20 0.32
CTSK P43235 1/20 0.32
CTSC P53634 1/20 0.32
CHRM1 P11229 1/20 0.31
AR P10275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5004185 1.00 PLD1 (0.38) PLD1OPRM1OPRL1OPRK1HTR2A
Hydrochloric Acid SCHEMBL4436906 0.99 PLD1 (0.38) PLD1OPRM1OPRL1OPRK1HTR2A
SCHEMBL4439004 0.98 PLD1 (0.38) PLD1OPRM1OPRL1OPRK1HTR2A
SCHEMBL4435630 0.90 PLD1 (0.36) PLD1OPRM1OPRL1OPRK1HTR2A
SCHEMBL4435819 0.89 OPRM1 (0.36) PLD1OPRM1OPRL1OPRK1HTR2A
SCHEMBL14146291 0.88 PLD1 (0.39) PLD1OPRM1OPRL1OPRK1HTR2A
SCHEMBL4437442 0.86 PLD1 (0.38) PLD1OPRM1OPRL1OPRK1HTR2A
SCHEMBL4433059 0.86 PLD1 (0.38) PLD1OPRM1OPRL1OPRK1HTR2A
Hydrochloric Acid SCHEMBL4440163 0.85 PLD1 (0.38) PLD1OPRM1OPRL1OPRK1HTR2A
SCHEMBL4438978 0.84 PLD1 (0.43) PLD1OPRM1OPRL1OPRK1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121656-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE Pfizer Products Inc. (US) 2009-11-25 EP claimed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US claimed
WO-2008084300-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER PRODUCTS INC. (US) 2008-07-17 WO claimed
EP-2121656-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE Pfizer Products Inc. (US) 2009-11-25 EP disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US disclosed
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER INC 2008-11-20 US disclosed
WO-2008084300-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE PFIZER PRODUCTS INC. (US) 2008-07-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287479-A1 INHIBITORS OF SERINE PALMITOYLTRANSFERASE SPTLC1, SPTLC2, CPT1A PLD1 351/4885OPRM1 4069/4885OPRL1 2087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.